Prostate Health and Testosterone: Debunking the Myths That Keep Men From Optimizing

The Biggest Myth in Men’s Health

For decades, the medical establishment operated under a simple but wrong assumption: testosterone causes prostate cancer. This belief was so deeply entrenched that it prevented millions of men from receiving testosterone therapy, kept researchers from investigating testosterone’s actual relationship with prostate health, and created a generation of men who feared their own primary sex hormone.

The origin of this myth traces back to Charles Huggins’ 1941 Nobel Prize-winning work showing that castration (removing testosterone) caused prostate cancer regression. The logical leap seemed obvious: if removing testosterone shrinks prostate cancer, then adding testosterone must cause it. This reasoning dominated urology for over 60 years. It was also fundamentally flawed.

The Saturation Model: What We Actually Know Now

The paradigm shifted with Abraham Morgentaler’s saturation model, published extensively from the mid-2000s onward. Morgentaler’s research demonstrated that prostate tissue has a finite capacity to respond to androgens — once androgen receptors are saturated (which occurs at relatively low testosterone levels, around 250 ng/dL), additional testosterone has minimal additional effect on prostate growth. This is a direct application of the Tony Huge Laws of Biochemistry Physics concerning receptor saturation and dose-response curves.

Think of it like watering a sponge. A dry sponge absorbs water rapidly — the first few ounces make a dramatic difference. But once the sponge is saturated, pouring more water on it doesn’t make it absorb more. Similarly, a prostate in a castrate environment (near-zero testosterone) will grow rapidly when testosterone is reintroduced. But a prostate already exposed to normal testosterone levels shows minimal additional growth when testosterone is increased further.

This explains Huggins’ observation perfectly: castration worked because it took testosterone below the saturation point, causing the cancer to shrink. But it doesn’t follow that levels above the saturation point cause cancer — the prostate is already maximally stimulated at normal physiological testosterone.

Multiple large-scale studies have since confirmed this model. The Endogenous Hormones and Prostate Cancer Collaborative Group analyzed pooled data from 18 prospective studies involving over 3,000 men with prostate cancer and found no significant association between circulating testosterone levels and prostate cancer risk. Men with higher testosterone were not more likely to develop prostate cancer than men with lower testosterone.

TRT and Prostate Cancer Risk: The Evidence

The TRAVERSE trial (2023), the largest randomized controlled trial of TRT to date, specifically monitored prostate cancer as a safety outcome. It found no increased risk of prostate cancer in men receiving testosterone compared to placebo over a median follow-up of 33 months. While the study duration was limited, it added to the growing body of evidence that TRT does not increase prostate cancer risk in men without pre-existing disease.

Meta-analyses of TRT studies have consistently shown no increased prostate cancer incidence in men receiving testosterone therapy. Some studies have actually suggested a possible protective effect of normal testosterone levels, though this remains speculative.

The current consensus among endocrinologists and urologists who stay current with the literature is that TRT is safe for men without active prostate cancer, TRT in men with a history of treated, low-risk prostate cancer is increasingly considered acceptable under careful monitoring, and the old blanket prohibition against testosterone in any man with prostate cancer history is being revised.

What Actually Affects Prostate Health

If testosterone doesn’t cause prostate cancer, what does influence prostate health? The factors with genuine evidence behind them include age (prostate cancer risk increases dramatically after 50 — it’s fundamentally an age-related disease), genetics and family history (first-degree relatives with prostate cancer roughly double your risk), chronic inflammation (prostatic inflammation from infections, diet, or metabolic dysfunction promotes cellular changes), insulin resistance and metabolic syndrome (strongly associated with more aggressive prostate cancer), obesity (higher body fat is associated with more advanced prostate cancer at diagnosis), and diet (high consumption of processed meats and low vegetable intake are consistently associated with higher risk).

Interestingly, several of these risk factors — insulin resistance, obesity, chronic inflammation — are the same conditions that suppress testosterone. This creates another paradox in the old paradigm: the metabolic states that lower testosterone are the same ones that increase prostate cancer risk. If testosterone caused prostate cancer, you’d expect the opposite relationship.

DHT: The More Nuanced Androgen

Dihydrotestosterone (DHT) deserves specific discussion because it’s more directly relevant to prostate physiology than testosterone itself. DHT is produced from testosterone by the enzyme 5-alpha reductase, and it’s the primary androgen acting on the prostate. DHT is 3-5 times more potent than testosterone at the androgen receptor.

5-alpha reductase inhibitors (finasteride, dutasteride) were studied in large cancer prevention trials. The PCPT trial found that finasteride reduced overall prostate cancer incidence by about 25%, but the cancers that did develop in the finasteride group were slightly more likely to be high-grade. This led to years of debate and ultimately the conclusion that finasteride didn’t actually cause aggressive cancers — it simply made them easier to detect by shrinking the prostate and improving biopsy accuracy.

For men using compounds that increase DHT (like testosterone, creatine, or compounds that bypass aromatase), PSA monitoring and prostate awareness are important but shouldn’t be driven by panic. Regular PSA testing (annually after age 50, or earlier with family history), awareness of urinary symptom changes, and open communication with a urologist who understands hormone optimization provide adequate monitoring.

Prostate-Protective Strategies for Hormone Optimizers

For men actively optimizing testosterone through any pathway — natural or pharmaceutical — several evidence-based strategies support prostate health. Regular exercise, particularly aerobic exercise, is consistently associated with lower prostate cancer risk and better outcomes. Maintaining a healthy body weight reduces both inflammation and insulin resistance. A diet rich in cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) provides compounds like sulforaphane and DIM that support healthy estrogen metabolism and have demonstrated anti-cancer properties in prostate cell studies.

Lycopene from tomatoes has the strongest dietary evidence for prostate protection — men with the highest lycopene intake consistently show lower prostate cancer risk across multiple large studies. Cooked tomatoes provide more bioavailable lycopene than raw.

Saw palmetto, while popular as a prostate supplement, has mixed evidence for cancer prevention. Its primary evidence base is for benign prostatic hyperplasia (BPH) symptom management, where it may offer modest benefit. It’s a mild 5-alpha reductase inhibitor, so men using it should be aware that it may slightly reduce DHT levels.

The Bottom Line for Natty Plus Practitioners

The fear that optimizing your testosterone will give you prostate cancer is not supported by modern evidence. The saturation model, large prospective studies, and the TRAVERSE trial have thoroughly dismantled the old paradigm. This doesn’t mean prostate health should be ignored — regular monitoring, healthy lifestyle practices, and awareness of symptoms remain important. But they’re important for all men over 50, regardless of whether they’re optimizing hormones.

The Natty Plus approach, which works through your body’s own regulatory mechanisms, is particularly well-suited to prostate safety. Natural testosterone optimization doesn’t create the supraphysiological hormone levels that might theoretically push past the saturation model’s safety margin. You’re working within the range your body was designed to handle — and the evidence says that range is safe for your prostate.